Sign inJoin waitlistJoin the waitlist

Renata Ferrarotto

Director of Head and Neck Medical Oncology Clinical Research · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Head and Neck Medical Oncology Clinical Research · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2012–2014
Medical Oncology
2009–2012
Internal Medicine
2006–2009
Doctor of Medicine
2002–2006

Research

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 855 citations
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial
JAMA Oncology · 2019 · 410 citations
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
JAMA Oncology · 2020 · 299 citations

Brandon Gunn
54 papers
Jack Phan
51 papers
David Rosenthal
47 papers
Adel El-Naggar
45 papers
Steven Frank
45 papers
Clifton Fuller
44 papers
Adam Garden
43 papers
Diana Bell
43 papers
Ehab Hanna
42 papers
BG
Bonnie Glisson
38 papers
Neil Gross
37 papers
William Morrison
30 papers

Grants

Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma
National Cancer Institute · R01
Contact PI · $1.1M · University of Tx Md Anderson Can Ctr
2024–2029
Exploring Biomarkers of Clinical Benefit to VEGFR Inhibitor Combined with PD-L1 Inhibitor in Recurrent/Metastatic Adenoid Cystic Carcinoma
National Institute of Dental and Craniofacial Research · R03
Contact PI · $324K · University of Tx Md Anderson Can Ctr
2022–2025

Clinical trials

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2031
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2023–2024
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2028
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2022–2023